Unit | % Patients (95% confidence interval) | |||||||||
1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006† | |||
Outpatient | ||||||||||
All MRSA | 26.8 (26.3-27.3) |
29.4 (29.0-29.9) |
33.4 (33.0-33.9) |
35.7 (35.3-36.2) |
40.7 (40.2-41.2) |
47.7 (47.3-48.1) |
52.7 (52.3-53.1) |
52.4 (52.0-52.9) |
||
HA-MRSA | 23.2 (23.0-23.5) |
25.1 (24.9-25.4) |
28.2 (28.0-28.5) |
28.4 (28.2-28.7) |
29.3 (29.0-29.5) |
28.4 (28.2-28.7) |
24.1 (23.8-24.3) |
24.2 (24.0-24.5) |
||
Blood | 2.7 | 2.8 | 4.0 | 3.7 | 3.1 | 2.8 | 2.1 | 1.9 | ||
Lungs | 4.7 | 5.3 | 6.5 | 5.5 | 5.4 | 4.2 | 3.5 | 2.9 | ||
Skin | 9.3 | 10.6 | 10.1 | 11.6 | 13.8 | 15.5 | 14.2 | 15.5 | ||
Other source | 6.4 | 6.5 | 7.6 | 7.7 | 7.0 | 6.0 | 4.2 | 4.0 | ||
CA-MRSA | 3.6 (3.5-3.7) |
4.3 (4.2-4.4) |
5.2 (5.1-5.4) |
7.3 (7.1-7.5) |
11.4 (11.3-11.6) |
19.3 (19.1-19.5) |
28.7 (28.4-28.9) |
28.2 (28.0-28.5) |
||
Blood | 0.3 | 0.3 | 0.6 | 0.7 | 0.8 | 0.8 | 0.9 | 0.8 | ||
Lungs | 0.4 | 0.5 | 0.9 | 0.9 | 0.7 | 0.6 | 0.8 | 0.7 | ||
Skin | 2.3 | 3.0 | 2.9 | 4.8 | 9.0 | 16.6 | 25.3 | 25.4 | ||
Other source | 0.5 | 0.5 | 0.8 | 0.9 | 1.0 | 1.3 | 1.6 | 1.4 | ||
Inpatient | ||||||||||
All MRSA | 46.7 (46.2-47.2) |
47.6 (47.2-48.1) |
50.0 (49.6-50.4) |
52.2 (51.8-52.6) |
54.9 (54.6-55.3) |
58.3 (57.9-58.6) |
59.5 (59.2-59.9) |
58.5 (58.0-58.9) |
||
HA-MRSA | 43.4 (43.0-43.9) |
43.2 (42.8-43.6) |
44.1 (43.7-44.5) |
43.9 (43.5-44.3) |
44.1 (43.7-44.5) |
41.9 (41.6-42.3) |
38.5 (38.2-38.9) |
38.7 (38.3-39.1) |
||
Blood | 7.1 | 7.2 | 7.5 | 7.5 | 7.5 | 7.0 | 6.2 | 6.3 | ||
Lungs | 21.4 | 19.9 | 19.2 | 18.5 | 17.6 | 16.5 | 14.7 | 14.5 | ||
Skin | 9.3 | 10.5 | 11.4 | 12.0 | 12.9 | 13.1 | 13.0 | 13.1 | ||
Other source | 5.6 | 5.6 | 6.0 | 5.9 | 6.1 | 5.3 | 4.5 | 4.7 | ||
CA-MRSA | 3.3 (3.1-3.4) |
4.5 (4.3-4.6) |
5.8 (5.6-6.0) |
8.4 (8.2-8.6) |
10.9 (10.6-11.1) |
16.3 (16.1-16.6) |
21.0 (20.7-21.3) |
19.8 (19.4-20.1) |
||
Blood | 0.6 | 0.7 | 1.0 | 1.2 | 1.2 | 1.7 | 2.1 | 2.0 | ||
Lungs | 1.2 | 1.6 | 2.1 | 2.3 | 2.1 | 2.6 | 3.3 | 3.8 | ||
Skin | 1.1 | 1.7 | 2.1 | 4.0 | 6.6 | 10.9 | 14.4 | 12.8 | ||
Other source | 0.4 | 0.5 | 0.7 | 0.9 | 1.0 | 1.2 | 1.3 | 1.2 |
Frequency of MRSA in Hospitals, by Unit, United States, 1999-2006*
*MRSA, methicillin-resistant Staphylococcus aureus; HA-MRSA, hospital-associated MRSA; CA-MRSA, community-associated MRSA.
†Data through October only. Data for blood, lungs, skin, and other source refer to the percentage of each source tested that
was estimated to be CA-MRSA or HA-MRSA.
This activity is intended for primary care physicians, infectious disease specialists, and other physicians who care for patients at risk for infection with methicillin-resistant Staphylococcus aureus (MRSA).
The goal of this activity is to describe the recent epidemiology of infection with methicillin-resistant Staphylococcus aureus (MRSA).
Upon completion of this activity, participants will be able to:
As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of MedscapeCME and Emerging Infectious Diseases.
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 0.5
AMA PRA Category 1 Credit(s)™
. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.
*The credit that you receive is based on your user profile.
CME Released: 11/23/2009
Valid for credit through: 11/23/2010
processing....
Abstract
Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) has become a major problem in US hospitals already dealing with high levels of hospital-associated MRSA (HA-MRSA). Using antimicrobial drug susceptibility data for 1999-2006 from The Surveillance Network, we characterized the relationship between outpatient and inpatient levels of CA-MRSA nationally. In outpatients, the frequency of CA-MRSA isolates has increased >7× during 1999-2006, which suggests that outpatients have become a major reservoir for CA-MRSA. However, contrary to results in other reports, although CA-MRSA increases are associated with decreases in the frequency of HA-MRSA in hospitals, the decreases are only modest. This finding suggests that instead of replacing HA-MRSA in the hospital, CA-MRSA is adding to the overall presence of MRSA already found within the hospital population.
Introduction
The past decade has seen a large increase in infections with hospital-associated methicillin-resistant Staphylococcus aureus (HA-MRSA).[1] MRSA is one of the most common causes of nosocomial infections, especially invasive bacterial infections,[2] and is now endemic and even epidemic to many US hospitals, long-term care facilities,[3] and communities.[4-6] Although community-associated MRSA (CA-MRSA) strains have been recognized as a leading cause of skin and soft tissue infections,[1,6] especially in patients with no established healthcare risk factors,[7,8] they also cause severe invasive infections.[9,10] Recent reports based on genotypic evidence have suggested that CA-MRSA is likely spreading within hospitals as well, blurring the line between CA-MRSA and HA-MRSA infections.[11]
Molecular typing studies have identified 2 MRSA clones, USA300 and USA400, as the primary types that cause CA-MRSA infections (12). Evidence suggests that emergence of these strains was independent of hospital strains.[13] Thus, understanding the role of outpatients, who are among the likely carriers of CA-MRSA into a hospital, is useful for understanding the changing epidemiology of MRSA in hospitals. Outpatients, who outnumber inpatients by ≈3:1, may play a major role in the spread of CA-MRSA strains from the community to the hospital through their interaction with hospital staff or use of similar hospital resources, such as surgical rooms. However, limited information hinders understanding of long-term trends in CA-MRSA in outpatients in the context of changing epidemiology of inpatients. This lack of information hinders the ability to evaluate infection control methods in the face of a possible emerging epidemic of nosocomial infections caused by CA-MRSA.
Knowledge of trends in antimicrobial drug resistance rates for emerging pathogens are useful to clinicians to ensure high-quality care, which is essential for antimicrobial drug therapy, in which different drugs can have different costs and effectiveness. These trends can also help hospital administrators and policy makers make infection control investments to address the role that large influxes of outpatients with CA-MRSA infections may play with regard to overall MRSA infection rates in the hospital.